Ennature Bio Pharma, the demerged entity from India Glycols, has started trading on Indian exchanges on November 4, 2026. Shareholders received one Ennature share for every three shares held in India Glycols. Investors should note the company's focus on branded nutraceuticals and its temporary trading status in the 'T' group.
Ennature Bio Pharma officially began trading on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on Wednesday, November 4, 2026. The company arrives on the stock market as a result of its separation from India Glycols Limited. Under the terms of the corporate restructuring, shareholders of India Glycols received one share of Ennature Bio Pharma for every three shares they held in the parent company.
The business focuses on three specific areas: Active Pharmaceutical Ingredients (API), biopolymers, and nutraceuticals. Currently, the API segment drives the majority of the company's performance, accounting for 67 percent of total sales. The nutraceutical division contributes 17 percent, while the biopolymer business makes up the remaining 16 percent.
For the 2026 fiscal year, the company reported a net revenue of ₹246 crore and an EBITDA of ₹29 crore, with a gross margin of 40.1 percent. The company manages manufacturing facilities in Dehradun and Kashipur, which hold international quality certifications such as USFDA, EU-GMP, and NSF-GMP. These certifications are important because a large portion of the revenue, particularly in the API and nutraceutical segments, is generated from exports to international markets.
Management has indicated that the nutraceutical division is the core area for future growth. The company aims to transition from basic extracts to high-value, proprietary branded ingredients like Aspargize, Gingeren, and Maxicuma. The success of this strategy will depend on the company's ability to scale these branded products internationally, where it currently serves over 90 clients across 19 countries.
Investors should be aware of a few specific operational and regulatory aspects. First, the stock has been placed in the 'T' group, or the trade-for-trade segment, for the first 10 trading days. This means that all trades in the stock must result in actual delivery of shares, with no intraday trading allowed. This usually restricts liquidity for the initial period following a listing.
Second, because the company relies heavily on exports—deriving 54 percent of its API revenue and 83 percent of its nutraceutical revenue from outside India—it remains sensitive to changes in international regulatory standards and global demand. Maintaining compliance with foreign quality regulators will remain a key monitorable for the business. Moving forward, shareholders will likely track how quickly the company can grow its branded nutraceutical portfolio and whether it can maintain its margins amidst global competition.